Tag: R-Pharm

R-Pharm localized full-cycle manufacturing of Glatirat

Yaroslavl Plant of Finished Dosage Forms and Biotechnological Substances completed the project to localize the full-cycle manufacturing of Glatirat

R-Pharm and PrimeBioMed will develop a quantitative immunohistochemical test

R-Pharm Group and PrimeBioMed LLC signed an agreement on joint development of a quantitative immunohistochemical test for the use of drugs blocking PD-1/PD-L1

R-Pharm completes the deal to sell a 10% stake to Mitsui

October 17 marked the closing of a deal on acquisition of a 10% stake in R-Pharm, a Russian pharmaceutical company, by Mitsui & Co., Ltd.

R-Pharm becomes the first Russian company to conduct clinical trials in South Korea

A meeting with the doctors and employees of 8 leading South Korean clinical and university centers was held in Seoul.

A fund established by RDIF and JBIC invests in R-Pharm

The first deal of the joint investment fund established by Japan Bank for International Cooperation and Russian Direct Investment Fund will be investment in R-Pharm

R-Pharm will help to introduce innovative diagnostic methods in Kazakhstan

On August 26, during the Eurasian Week held in Astana, ULNANOTECH, LLP R-Pharm Kazakhstan and LLC TestGen signed a cooperation agreement.

Phase III clinical study of Remimazolam starts in Russia

R-Pharm began the Phase III clinical study of the medicine used to induce and maintain the general anesthesia

Otsuka and R-Pharm sign a licensing agreement to market Deltyba

Otsuka Pharmaceutical Co. Ltd. and R-Pharm Group signed a licensing agreement to manufacture and market Deltyba

R-Pharm and Aspyrian Therapeutics signed an exclusive licensing agreement

R-Pharm Overseas, Inc., a division of R-Pharm Group, signed an exclusive licensing agreement with Aspyrian Therapeutics Inc.

MSD and R-Pharm invested 200 million rubles in the localization of Raltegravir

MSD, an international biopharmaceutical company, and R-Pharm, a leading Russian pharmaceutical company, have announced the successful completion of their joint project

R-Pharm plans to launch its products onto the Japanese market

In three years, the Russian pharmaceutical company R-Pharm intends to launch some of its medicines onto the Japanese market.

R-Pharm and Nacimbio established a joint venture

National Immunobiological Company, a part of Rostec Corporation, and R-Pharm, a Russian pharmaceutical company, signed an agreement to establish a joint venture.

New product of R-Pharm will reduce the cost of HCV treatment

On April 25, Vladimir Putin met the representatives of businesses in the Yaroslavl region. The event was attended by Vasily Ignatiev, the CEO of R-Pharm Group. The CEO of R-Pharm mentioned the suppor...

R-Pharm releases first batch of medicines with protective labeling

On March 14, ORTAT, a pharmaceutical plant of R-Pharm Group, released the first batch of Herceptin, a medicine, with DataMatrix code. 2D code on the package of the medicinal product fully complies wit...

R-Pharm and FUJIFILM Corporation Sign Agreement on Comprehensive Cooperation in the Field of Healthc...

R-Pharm group and FUJIFILM Corporation signed an agreement on healthcare cooperation on the sidelines of the Russian-Japanese dialogue within the visit of the President of the Russian Federation V.V. ...

The first Immuno-Oncology Drug of the Innovative PD-1 Inhibitor Class has been Approved in Russia

MSD, known as Merck & Co. in the United States and Canada, informs that the first-in-class of the PD-1 inhibitors immuno-oncology drug, pembrolizumab, has been approved in Russia. This drug is ind...